S1 Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.s1biopharma.com
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)One-Year Study of S1B-509 vs Placebo for Weight Loss
Phase 2
Not yet recruiting
- Conditions
- Obesity
- Interventions
- Drug: S1B-509 low doseDrug: PlaceboDrug: S1B-509 High Dose
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- S1 Biopharma, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06517797
Study of S1B-408 in Women With Orgasmic Dysfunction
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- S1 Biopharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06516055
Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety
Phase 1
Completed
- Conditions
- Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined)Sexual Interest/Arousal Disorder (DSM-5 Defined)
- Interventions
- Drug: bupropion, Lorexys low-dose, Lorexys moderate-dose
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- S1 Biopharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01857596
- Locations
- 🇺🇸
Robert Taylor Segraves, MD, PhD, Beachwood, Ohio, United States
🇺🇸Molly Katz, MD, Cincinnati, Ohio, United States
News
No news found